Impact of immunotherapy with autologous activated T-lymphocytes on clinical parameters and quality of life in patients with allergic bronchial asthma

Aim. To assess the impact of autologous activated T-lymphocyte immunotherapy on clinical parameters and quality of life in patients with allergic bronchial asthma (BA) in comparison with patients with allergic BA who received standard therapy.

Materials and methods. A non-randomized, pilot study included 19 patients with allergic BA of moderate severity (7 men and 12 women aged 23–61 years, average age – 38.5 ± 4.3 years) who received the T-cell vaccine (n = 12) and standard therapy with inhaled glucocorticoids, short- and long-acting β2-adrenergic agonists (n = 7). After signing an informed consent, the patients were subcutaneously injected with autologous activated T-lymphocytes with a frequency of 4 injections 1 time / week, and then 6 injections 1 time / month. The research methods included asthma control measurement according to the ACQ-5 questionnaire and quality of life assessment according to the AQLQ(S) questionnaire. Clinical data were collected during lung function tests and by measuring the total immunoglobulin E (IgE) level.

Results. In the course of the study, the immunotherapy was well tolerated, no systemic adverse reactions were noted. The treatment approach in the patients who received the T-cell vaccine resulted in significant improvement of asthma control parameters (according to the ACQ-5 questionnaire) and parameters of the patients’ quality of life (according to the AQLQ(S) questionnaire) within all 4 categories. Besides, their lung function improved by the end of treatment, and the total IgE level decreased. No significant changes in these parameters were observed during the follow-up in patients who received standard therapy. The study was conducted before immunotherapy, after 2 months (after 5 injections), and after 7 months (after 10 injections).

Conclusion. Evaluation of the impact of immunotherapy with autologous activated T-lymphocytes on the clinical parameters and quality of life in patients with BA indicates effectiveness of treatment in patients with allergic BA.

1. Global Strategy for Asthma Management and Prevention. Revised 2016. URL: https://ginasthma.org/archived-reports/

2. World Health Organization. URL: http://www.who.int/ru/news-room/fact-sheets/detail/asthma

3. Российское респираторное общество. URL: https://spulmo.ru/upload/kr_bronhastma_2019.pdf

4. Sharabi A. et al. Regulatory T cells in the treatment of disease. Nature Reviews Drug Discovery. 2018. 17(11):823–844. DOI: 10.1038/nrd.2018.148

5. Блинова Е.А., Пашкина Е.А., Тевс А.Е. и др. Т-клеточные вакцины: обоснование и первый опыт клинического применения. Биотехнология – медицине будущего: Материалы Всероссийской конференции с международным участием, Новосибирск; 24–26 июля 2017 г.; Новосибирск: Офсет-ТМ, 2017:25. URL: https://elibrary.ru/item.asp?id=39151728

6. Кожевников В.С., Королькова О.Ю. Антиэрготипический ответ в эксперименте и клинике. Иммунопатогенез и иммунотерапия основных заболеваний человека: от эксперимента к клинике: материалы 8-й отчетной конференции Научно-исследовательского института клинической иммунологии СО РАМН, Новосибирск, 2123 июня 2011 г.; Научно-исследовательский институт клинической иммунологии СО РАМН, Новосибирск: Сибмед-издат НГМУ, 2011:106–107. URL: https://elibrary.ru/item.asp?id=21166234

7. Патент РФ на изобретение № 2652752/28.04.2018. Бюл. № 13, Е.А. Блинова, Е.А. Пашкина, А.Е. Тевс, В.М. Непомнящих, М.И Леонова, Д.В. Демина, В.А. Козлов. Способ лечения бронхиальной астмы. URL: https://www.fips.ru/cdfi/fips.dll/ru?ty=29&docid=2652752

8. Bateman E.D., Reddel H.K., Eriksson G., Peterson S., Ostlund O., Sears M.R. et al. Overall asthma control: the relationship between current control and future risk. J. Allergy Clin. Immunol. 2010;125(3):600–608. DOI: 10.1016/j.jaci.2009.11.033.

9. Шестакова Н.А., Кожевников В.С. Влияние иммунотерапии активированными Т-лимфоцитами на параметры клеточного иммунитета больных разными формами атопического дерматита. Acta Biomedica Scientifica. 2012;3(2):226–230. URL: https://elibrary.ru/item.asp?id=17903344

10. Авдеев С.Н. Опросник ACQ – новый инструмент оценки контроля над бронхиальной астмой. Пульмонология. 2014;(2):93–99. URL: https://journal.pulmonology.ru/pulm/article/download/310/308